Importantly, over half of metastatic sites demonstrated expression of HER2 and HER3 with stromal expression of ASPN, suggesting this signaling mechanism may have critical roles in metastatic prostate cancer. The gene discussed is ASPN; the disease is metastatic prostate carcinoma.